36 cases of advanced NSCLC by combined chemotherapy based on gemcitabine
- VernacularTitle:吉西他滨为主联合方案治疗36例晚期非小细胞肺癌
- Author:
Cheng HUANG
- Publication Type:Journal Article
- Keywords:
gemcitabine;
combination chemotherapy;
non-small-cell lung cancer
- From:China Oncology
2000;0(06):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose:To investigate clinical effects and side reactions of advanced NSCLC by combined chemotherapy base on gemcitabine. Methods:36 cases of advanced NSCLC were divided into two groups: Group 1, 20 cases were treated by gemcitabine 1.6 g at d1,d8,d15 and 80mg/m 2 DDP at d1; Group 2,16 cases were treaded by gemcitabine 1.6 g and paclitaxel 60 mg at d1,d8,d15.Both groups were repeated every 4 weeks and clinical effects were evaluated after 3 cycles.Results:CR 1 case, PR 17 cases, SD 16 cases, PD 2 cases and CR+PR 18 cases (response rate 50 0%) in 36 cases observed. In 20 cases primary treatments:CR+PR 11cases (response rate 55 0%);In 16 cases re-treatments: CR+ PR 7 cases (response rate 43.75%); In 15 cases of advanced NSCLC re-treated by gemcitabine combined with paclitaxel: CR+PR 7 cases (response rate 46.7%). Side reaction: most cases showed bone marrow suppression and symptoms of gastrointestinal side-effects, which included 12 cases of Ⅲ-Ⅳ grades leukocytopenia (33.3%),7 cases of Ⅱ-Ⅲ grades soterocytopenia (19.4%),8 cases of Ⅲ-Ⅳ grades symptoms of gastrointestinal side-effects (22.2%),2 cases of Ⅱ grades abnormal liver function.Conclusions:Better clinical effects have been achieved in the therapy of advanced NSCLC by combined methods based on gemcitabine and side-reactions are tolerable;Nice effects were obtained in the re-treatment of NSCLC by gemcitabine combined with paclitaxel.It is valuable to investigate its Clinical effects more deeply.
